115 related articles for article (PubMed ID: 38659267)
1. Anlotinib Inhibiting Mantle Cell Lymphoma Proliferation and Inducing Apoptosis through PI3K/AKT/mTOR Pathway.
Wang J; Xu Z; Lai Y; Zhang Y; Zhang P; Mu Q; Yang S; Sheng L; Ouyang G
Curr Mol Med; 2024 Apr; ():. PubMed ID: 38659267
[TBL] [Abstract][Full Text] [Related]
2. Xihuang pills induce apoptosis in hepatocellular carcinoma by suppressing phosphoinositide 3-kinase/protein kinase-B/mechanistic target of rapamycin pathway.
Teng YJ; Deng Z; Ouyang ZG; Zhou Q; Mei S; Fan XX; Wu YR; Long HP; Fang LY; Yin DL; Zhang BY; Guo YM; Zhu WH; Huang Z; Zheng P; Ning DM; Tian XF
World J Gastrointest Oncol; 2022 Apr; 14(4):872-886. PubMed ID: 35582102
[TBL] [Abstract][Full Text] [Related]
3. Concurrent inhibition of PI3K and mTORC1/mTORC2 overcomes resistance to rapamycin induced apoptosis by down-regulation of Mcl-1 in mantle cell lymphoma.
Müller A; Zang C; Chumduri C; Dörken B; Daniel PT; Scholz CW
Int J Cancer; 2013 Oct; 133(8):1813-24. PubMed ID: 23580240
[TBL] [Abstract][Full Text] [Related]
4. The dual PI3K and mTOR inhibitor NVP-BEZ235 exhibits anti-proliferative activity and overcomes bortezomib resistance in mantle cell lymphoma cells.
Kim A; Park S; Lee JE; Jang WS; Lee SJ; Kang HJ; Lee SS
Leuk Res; 2012 Jul; 36(7):912-20. PubMed ID: 22560334
[TBL] [Abstract][Full Text] [Related]
5. Anlotinib Inhibits Proliferation and Induces Apoptosis in B-cell Acute Lymphoblastic Leukemia by Targeting the BTK and AKT/mTOR Pathway.
Shi X; Li S; Tang S; Lu Y
Anticancer Agents Med Chem; 2023; 23(12):1397-1405. PubMed ID: 36856175
[TBL] [Abstract][Full Text] [Related]
6. Dual PI3K/mTOR inhibition is required to effectively impair microenvironment survival signals in mantle cell lymphoma.
Rosich L; Montraveta A; Xargay-Torrent S; López-Guerra M; Roldán J; Aymerich M; Salaverria I; Beà S; Campo E; Pérez-Galán P; Roué G; Colomer D
Oncotarget; 2014 Aug; 5(16):6788-800. PubMed ID: 25216518
[TBL] [Abstract][Full Text] [Related]
7. Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma.
Peponi E; Drakos E; Reyes G; Leventaki V; Rassidakis GZ; Medeiros LJ
Am J Pathol; 2006 Dec; 169(6):2171-80. PubMed ID: 17148679
[TBL] [Abstract][Full Text] [Related]
8. Anlotinib Inhibits Cisplatin Resistance in Non-Small-Cell Lung Cancer Cells by Inhibiting MCL-1 Expression via MET/STAT3/Akt Pathway.
Wang L; Xu L; Han S; Zhu X
Can Respir J; 2024; 2024():2632014. PubMed ID: 38468814
[TBL] [Abstract][Full Text] [Related]
9. Anlotinib Overcomes Multiple Drug Resistant Colorectal Cancer Cells via Inactivating PI3K/AKT Pathway.
Lan W; Zhao J; Chen W; Shang H; Peng J; Lin J
Anticancer Agents Med Chem; 2021; 21(15):1987-1995. PubMed ID: 33438566
[TBL] [Abstract][Full Text] [Related]
10. Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism.
Rahmani M; Aust MM; Attkisson E; Williams DC; Ferreira-Gonzalez A; Grant S
Cancer Res; 2013 Feb; 73(4):1340-51. PubMed ID: 23243017
[TBL] [Abstract][Full Text] [Related]
11. miR-100 inhibits cell proliferation in mantle cell lymphoma by targeting mTOR.
Lin L; Huang Y; Zhuang W; Lin P; Ma X
Exp Hematol Oncol; 2020; 9():25. PubMed ID: 32999755
[TBL] [Abstract][Full Text] [Related]
12. Anlotinib suppresses tumor progression via blocking the VEGFR2/PI3K/AKT cascade in intrahepatic cholangiocarcinoma.
Song F; Hu B; Cheng JW; Sun YF; Zhou KQ; Wang PX; Guo W; Zhou J; Fan J; Chen Z; Yang XR
Cell Death Dis; 2020 Jul; 11(7):573. PubMed ID: 32709873
[TBL] [Abstract][Full Text] [Related]
13. The tumour suppressor FOXO3 is a key regulator of mantle cell lymphoma proliferation and survival.
Obrador-Hevia A; Serra-Sitjar M; Rodríguez J; Villalonga P; Fernández de Mattos S
Br J Haematol; 2012 Feb; 156(3):334-45. PubMed ID: 22107151
[TBL] [Abstract][Full Text] [Related]
14. The Synthetic Compound Norcantharidin Induced Apoptosis in Mantle Cell Lymphoma In Vivo and In Vitro through the PI3K-Akt-NF- κ B Signaling Pathway.
Lv H; Li Y; Du H; Fang J; Song X; Zhang J
Evid Based Complement Alternat Med; 2013; 2013():461487. PubMed ID: 23935664
[TBL] [Abstract][Full Text] [Related]
15. Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma.
Dal Col J; Zancai P; Terrin L; Guidoboni M; Ponzoni M; Pavan A; Spina M; Bergamin S; Rizzo S; Tirelli U; De Rossi A; Doglioni C; Dolcetti R
Blood; 2008 May; 111(10):5142-51. PubMed ID: 18339899
[TBL] [Abstract][Full Text] [Related]
16. PIK-75 overcomes venetoclax resistance
Huang S; Liu Y; Chen Z; Wang M; Jiang VC
Am J Cancer Res; 2022; 12(3):1102-1115. PubMed ID: 35411248
[TBL] [Abstract][Full Text] [Related]
17. PI3K inhibitor impairs tumor progression and enhances sensitivity to anlotinib in anlotinib-resistant osteosarcoma.
Chen C; Guo Y; Huang Q; Wang B; Wang W; Niu J; Lou J; Xu J; Ren T; Huang Y; Guo W
Cancer Lett; 2022 Jun; 536():215660. PubMed ID: 35318116
[TBL] [Abstract][Full Text] [Related]
18. Anlotinib inhibits the proliferation and induces apoptosis by inactivating the AKT pathway in androgen receptor-negative prostate cancer cells.
Xu Y; Zheng J; Ye ZY
Neoplasma; 2022 Sep; 69(5):1119-1128. PubMed ID: 36004650
[TBL] [Abstract][Full Text] [Related]
19. Lipid raft-mediated Akt signaling as a therapeutic target in mantle cell lymphoma.
Reis-Sobreiro M; Roué G; Moros A; Gajate C; de la Iglesia-Vicente J; Colomer D; Mollinedo F
Blood Cancer J; 2013 May; 3(5):e118. PubMed ID: 23727661
[TBL] [Abstract][Full Text] [Related]
20. Anlotinib inhibits growth of human esophageal cancer TE-1 cells by negative regulating PI3K/Akt signaling pathway.
Liu Y; Li F; Wang Q; Zhang Y; Tian S; Li B
Discov Oncol; 2024 Apr; 15(1):134. PubMed ID: 38678128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
